CD8 T Cells Contribute to Vaccine Protection Against SARS-CoV-2 in Macaques
Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions
Vaccine protection against the SARS-CoV-2 Omicron variant in macaques
Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
Spatial and Genomic Correlates of HIV-1 Integration Site Targeting
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
Vaccines Elicit Highly Conserved Cellular Immunity to SARS-CoV-2 Omicron
Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women
Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
Correlates of protection against SARS-CoV-2 in rhesus macaques
Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
Approaches and Challenges in SARS-CoV-2 Vaccine Development
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
SARS-CoV-2 infection protects against rechallenge in rhesus macaques
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
Lack of therapeutic efficacy of an antibody to α4β7 in SIVmac251-infected rhesus macaques.
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).